177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR How People With Cancer Can Benefit From Online Therapy October 22, 2020 FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma October 27, 2022 Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed... January 20, 2025 Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home July 30, 2021 Load more HOT NEWS Newest Gerber Baby is Child of Breast Cancer Survivor Can I Have a Nonviolent Relationship with Cancer? (Part 1) From athlete to wig-maker: how cancer changed Maria’s destiny Women in science: Cancer research pioneers – part 1
